Related Experiment Video
Updated: Mar 12, 2026
03:53
Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis
Published on: December 29, 2023
1.3K
Betrixaban - the next direct factor Xa inhibitor?
Martin Thoenes1,2, Joan Minguet3, Karin Bramlage3
1a Léman Research Institute , Neuhausen am Rheinfall , Switzerland.
Expert Review of Hematology
|November 5, 2016
Summary
Betrixaban, a new direct oral anticoagulant (DOAC), shows antithrombotic potential. Its favorable metabolism may benefit patients with kidney or liver issues, but a reversal agent is needed.
Area of Science:
- Pharmacology and Thrombosis Research
- Drug Metabolism and Pharmacokinetics
- Clinical Trial Analysis
Background:
- Venous thromboembolism (VTE) poses a significant global health challenge.
- Conventional anticoagulants like heparin and warfarin have been mainstays since the 1930s.
- Direct oral anticoagulants (DOACs) have emerged as alternatives, with betrixaban as a potential fifth option.
Purpose of the Study:
- To review the metabolism, pharmacokinetics, and pharmacodynamics of betrixaban.
- To summarize the clinical efficacy and safety of betrixaban from phase II/III trials.
- To assess betrixaban's potential role among existing DOACs.
Main Methods:
- Literature review of metabolism, pharmacokinetics, and pharmacodynamics.
- Analysis of clinical trial data (phase II/III) for efficacy and safety.
- Comparison with established anticoagulants and other DOACs.
Main Results:
- Betrixaban exhibits antithrombotic activity.
- Low renal clearance and minimal hepatic metabolism suggest potential benefits for patients with renal or hepatic dysfunction.
- A longer terminal half-life necessitates consideration regarding the lack of a reversal agent.
Conclusions:
- Betrixaban may be a valuable addition to the DOAC class.
- Its pharmacokinetic profile could be advantageous for specific patient populations.
- Further large-scale randomized trials are crucial to confirm efficacy and safety.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
01:29Venous Thrombosis III: Interprofessional Care
445
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
445
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
01:16Clot Retraction and Fibrinolysis
9.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.9K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.7K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.7K